Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Background Pre-eclampsia is a hypertensive disorder of pregnancy which may cause morbidity and even mortality for both the mother and the fetus. Blood pressure elevation is the most visible sign of pre-eclampsia; however, the disease is multi-systemic affecting almost all systems of the body. CA125 has been found to be elevated in normal and pre-eclamptic pregnancies. Objectives To assess the level of CA-125 in normal and pre-eclamptic pregnancies to find out whether this marker is significantly elevated in women with pre-eclampsia, also to find out any correlation between the severity of pre-eclampsia and the serum concentration of CA 125. Patients and Methods This was a case control study, carried out in Sulaimani Maternity teaching hospital over a period of one year starting from the 1st of May 2015 to the 30th of April 2016. The study included 150 pregnant women, with singleton pregnancy in their 3rd trimester, these women were categorized into three group, fifty women with healthy pregnancy (the control group). Fifty women with mild pre-eclampsia and fifty women with severe pre-eclampsia (the study groups). The serum CA125 level was measured for the women in the three groups and comparison was made among them. Results Mean serum CA-125 and mean arterial pressure were significantly higher in the pre-eclamptic groups compared to the control group (P- value =0.0001). There was a direct correlation between CA-125 and mean arterial pressure in pregnant women with severe pre-eclampsia. The sensitivity and specificity of CA- 125 level were 94% for the detection of pre-eclamptic pregnancies. Conclusion Serum CA-125 was significantly higher in pre-eclampsia groups in comparison to the control group and the level was directly correlated with the severity of pre-eclampsia.
Background Pre-eclampsia is a hypertensive disorder of pregnancy which may cause morbidity and even mortality for both the mother and the fetus. Blood pressure elevation is the most visible sign of pre-eclampsia; however, the disease is multi-systemic affecting almost all systems of the body. CA125 has been found to be elevated in normal and pre-eclamptic pregnancies. Objectives To assess the level of CA-125 in normal and pre-eclamptic pregnancies to find out whether this marker is significantly elevated in women with pre-eclampsia, also to find out any correlation between the severity of pre-eclampsia and the serum concentration of CA 125. Patients and Methods This was a case control study, carried out in Sulaimani Maternity teaching hospital over a period of one year starting from the 1st of May 2015 to the 30th of April 2016. The study included 150 pregnant women, with singleton pregnancy in their 3rd trimester, these women were categorized into three group, fifty women with healthy pregnancy (the control group). Fifty women with mild pre-eclampsia and fifty women with severe pre-eclampsia (the study groups). The serum CA125 level was measured for the women in the three groups and comparison was made among them. Results Mean serum CA-125 and mean arterial pressure were significantly higher in the pre-eclamptic groups compared to the control group (P- value =0.0001). There was a direct correlation between CA-125 and mean arterial pressure in pregnant women with severe pre-eclampsia. The sensitivity and specificity of CA- 125 level were 94% for the detection of pre-eclamptic pregnancies. Conclusion Serum CA-125 was significantly higher in pre-eclampsia groups in comparison to the control group and the level was directly correlated with the severity of pre-eclampsia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.